AquaNab, a Hamburg-based biotech company, has secured an early-stage investment from Nordic Foodtech VC to advance its nanoantibody platform targeting diseases in aquaculture. The funding will support the development and commercialization of precision biologics designed to address major health challenges in fish farming, with sea lice in salmon production serving as the initial focus.
A Targeted Solution to an Industry Problem
Sea lice represent a significant economic and welfare challenge for European salmon producers. The parasitic crustaceans attach to farmed fish, causing stress, injury, and secondary infections that result in substantial losses across the industry. Current management approaches force producers into difficult compromises—either investing in expensive and labor-intensive treatments that stress the animals, or accepting productivity losses from untreated infestations.
AquaNab’s approach leverages nanoantibodies, engineered proteins derived from camelid antibodies that are considerably smaller than conventional antibodies. These molecules can be incorporated into fish feed, offering a non-invasive method to help salmon mount targeted immune responses against sea lice and other aquaculture pathogens.
“Sea lice is just the start,” said Dr Ruth Tamara Montero, commenting on the company’s vision. “Right now, producers are stuck choosing between costly, stressful treatments and losses from the parasite itself. We want to give them a way out of that cycle, one that protects their fish, their business, and helps secure the future of food.”
Next Steps for Development
The investment will enable AquaNab to progress through several critical development phases. The company plans to conduct proof-of-concept studies validating its nanoantibody technology in practical salmon farming conditions. Simultaneously, AquaNab will establish collaborative partnerships with salmon producers, feed manufacturers, and animal health companies to refine its approach and prepare for market introduction.
Commercialization efforts will focus on developing the first products ready for industry deployment, with the goal of providing farmers with a viable alternative to existing sea lice management strategies.
European Aquaculture Innovation Context
AquaNab’s funding reflects broader European investment momentum in agricultural biotechnology and aquaculture innovation. As regulatory pressures mount on conventional aquaculture practices and consumer expectations around animal welfare intensify, precision biotechnology solutions addressing production challenges have attracted growing venture attention. The aquaculture sector, representing a critical food production system across Northern Europe and beyond, increasingly relies on technological innovation to balance productivity with sustainability and animal health standards.
Nordic Foodtech VC’s backing of AquaNab underscores investor confidence in biology-based solutions for the foodtech sector, particularly those addressing concrete operational challenges faced by producers. The startup’s Hamburg location positions it within Germany’s growing biotech ecosystem while maintaining proximity to major salmon farming markets in Scandinavia.